Meeting Archive:
An ASBMR Webinar on Type 2 Diabetes and Fracture Risk

To listen to the recording and view the slides that were presented, click on the recording link on the right side of this screen. 

Meeting Description:

Type 2 diabetes is associated with increased fracture risk at the hip and other sites.  Surprisingly, BMD is not reduced, suggesting that diabetic bone is more fragile for a given BMD.  An important clinical implication of this paradox is that BMD T-score and the FRAX algorithm underestimate fracture risk in patients with type 2 diabetes.  The reasons for increased bone fragility in diabetes are not clear but some clues are emerging, including reduced bone formation rate, possible increases in cortical porosity, and higher levels of advanced glycation endproducts.  Treatments for diabetes may also affect the skeleton.  Options for fracture prevention in diabetic patients include glycemic control as well as established therapies for osteoporosis.  

As a result of this webinar participants will be able to:
  • Appreciate that BMD T-score and FRAX underestimate fracture risk in patients with type 2 diabetes.
  • Identify potential reasons for increased bone fragility in diabetic patients.
  • Describe current knowledge regarding fracture prevention in diabetic patients.
Date: Tue, Aug 13, 2013
Time: 12:00 PM EDT
Duration: 1 hour
Host(s): American Society for Bone and Mineral Research
 Presenter Information
Ann V. Schwartz, Ph.D.
Speaker Photo

Dr. Schwartz is Associate Professor of Epidemiology and Biostatistics at University of California San Francisco.  Her research focuses on understanding the clinical and translational aspects of fractures, osteoporosis and falls in older adults with diabetes.  She has published on the increased risk of fractures and falls and on the limitations of standard tools in assessing fracture risk in this population as well as the negative effects of  thiazolidinediones on skeletal health.  Dr. Schwartz is pursuing investigations into the reasons for reduced bone strength in type 2 diabetes including the accumulation of advanced glycation endproducts in bone collagen, increases in cortical porosity and changes in bone marrow adiposity.